Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Switzerland
/
Pharmaceuticals & Biotech
/
Roche Holding
ROG
Roche Holding
Regulatory Scrutiny And Generic Competition Will Erode Pricing Power
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
02 Jun 25
Updated
09 Aug 25
2
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CHF 230.00
7.1% overvalued
intrinsic discount
09 Aug
CHF 246.40
Loading
1Y
-11.8%
7D
-3.5%
Author's Valuation
CHF 230.0
7.1% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CHF 230.0
7.1% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
68b
2014
2017
2020
2023
2025
2026
2028
Revenue CHF 59.1b
Earnings CHF 11.7b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
2.92%
Pharma revenue growth rate
1.02%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
3.82%
Calculation
CHF 11.69b
Earnings '28
x
17.50x
PE Ratio '28
=
CHF 204.57b
Market Cap '28
CHF 204.57b
Market Cap '28
/
794.90m
No. shares '28
=
CHF 257.35
Share Price '28
CHF 257.35
Share Price '28
Discounted to 2025 @ 3.82% p.a.
=
CHF 229.98
Fair Value '25